Labiotech.eu

News and Trends 30 Mar 2015

#BioFigures: €406 Million Antibody-drug conjugate Deal struck by ImmunoGen andTakeda

WHO? ImmunoGen is a biotechnology company that develops targeted anticancer therapeutics using its state-of-the-art antibody-drug conjugate (ADC) technology. The Company’s uses tumor-targeting antibodies to deliver an ImmunoGen cell-killing agent specifically to cancer cells. The first product with ImmunoGen’s ADC technology is Roche‘s Kadcyla. ImmunoGen has three wholly owned product candidates in clinical testing with additional compounds […]

March 30, 2015 - 3 minutesmins - By Marie Godar

News and Trends 28 Mar 2015

Strategic Partnership Between Green Cross and Nanolek

The South Korean biopharmaceutical company Green Cross and the Russian pharmaceutical company Nanolek signed a strategic partnership agreement for the commercialisation of Green Cross’ biologics in the Russian market. Green Cross provides healthcare solutions that address the evolving needs of human health. The company is specialised in the development and manufacturing of plasma-derivatives, vaccines and recombinant […]

March 28, 2015 - 2 minutesmins - By Julie Lellouche

News and Trends 27 Mar 2015

OSE Pharma raised €21.1 Million

OSE Pharma’s Initial Public Offering couldn’t have been more successful as it just raised €21.1M. Noticing the strong demand for shares, the board of OSE Pharma has increased the price of the capital to €10.80 per share, corresponding to the top of the indicative price range of the offer. On this basis, the market capitalization […]

March 27, 2015 - 1 minutemin - By Lourdes Riquelme

News and Trends 26 Mar 2015

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

Exactly one month ago, the article “Cellectis is preparing its IPO in the U.S” explained Cellectis prepared an IPO to be listed on the NASDAQ. Yesterday, the company announced the pricing of its initial public offering. Its goal is to raise €197M and up to €226.8M in case of allotment. A large amount of ressources […]

March 26, 2015 - 2 minutesmins - By Joachim Eeckhout

metamorphosis biopharmceutical innovation bio europe spring 2015

News and Trends 26 Mar 2015

The Metamorphosis of Biopharmaceutical Innovation #BIO-Europe2015

Innovation can occur in many different ways, and biopharmaceutical innovation is no exception. The pipelines of big Pharmas have fewer candidates, R&D costs are skyrocketing, internal research programs tend to shrink and open innovation is raising. This metamorphosis is happening right now and the plenary session of Bio-Europe Spring 2015 focused on this subject. A great opportunity […]

March 26, 2015 - 6 minutesmins - By Philip Hemme

News and Trends 26 Mar 2015

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

After successfully complete phase I clinical study, apceth initiates the Phase II of world’s first genetically-engineered cell therapy. The ongoing monocentric Phase I/II clinical trial TREAT-ME 1 with the engineered cell therapeutic product Agenmestencel-T, will take place at the Klinikum Grosshadern in Munich. This is the first time that a genetically engineered Mesenchymal Stem Cell […]

March 26, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 26 Mar 2015

The Genomic Portrait of Iceland

A package of four landmark papers were published yesterday in the online edition of Nature Genetics. The research, written by a team of deCODE scientists, was built on whole-genome sequence data from more than 100,000 people from across Iceland. The four milestone studies together present the most detailed portrait of a population yet assembled using the latest technology […]

March 26, 2015 - 4 minutesmins - By Lourdes Riquelme

News and Trends 25 Mar 2015

Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer

Epigenomics, the German-American cancer molecular diagnostics company, completed the enrollment for its ADMIT trial (AD herence to Minimally Invasive Testing) for Epi proColon, its non-invasive blood-based test for colorectal cancer (CRC) screening. Epigenomics has successfully completed enrollment in the ADMIT clinical trial this week. Study subjects were identified as historically non-compliant to CRC screening according to […]

March 25, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 25 Mar 2015

The Institut Pasteur and IntegraGen, allies to Strengthen High-Throughput Sequencing in Microbiology

IntegraGen and the Institut Pasteur signed an agreement for high-throughput sequencing in the field of Microbiology. IntegraGen will be responsible for the technical and operational implementation of high-throughput sequencing activities for use by the microbiology experts at the National Reference Center (NRC) at the Institut Pasteur. High-throughput sequencing will be the reference tool for analysis, […]

March 25, 2015 - 2 minutesmins - By Lourdes Riquelme

News and Trends 24 Mar 2015

Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million

Rigontec has raised €4.8M in the second closing of its Series A financing round from Forbion Capital Partners, a Dutch life-sciences venture capital firm, and Sunstone Capital, a Copenhagen based venture capital investor. The new investment brings the total Series A to €14.2M to the biopharmaceutical company that is developing RNA-based immunotherapeutics for the treatment of […]

March 24, 2015 - 3 minutesmins - By Lourdes Riquelme

News and Trends 23 Mar 2015

Life Sciences have a new big player: Joint Polish Investment Fund Management

Poland’s first Institutional Venture Capital Fund dedicated to Life Sciences announced today the first closing of its new venture capital fund at €38.5M. Joint Polish Investment Fund Management (JPIF), headed by Dr. Marek Orłowski, is the first institutional venture capital fund operating out of Poland that is completely dedicated to life science investments. The fund […]

March 23, 2015 - 3 minutesmins - By Lourdes Riquelme

AOP Orphan Pharmaceuticals Confluence Pharmaceuticals Fragile X

News and Trends 23 Mar 2015

AOP Orphan and Confluence Pharmaceuticals, together for Fragile X Syndrome

AOP Orphan Pharmaceuticals and Confluence Pharmaceuticals, signed today a definitive agreement to co-develop and market Confluence’s lead asset, a product for the treatment of Fragile X Syndrome in Europe and the Middle East. Confluence is an American biopharmaceutical company focused on developing therapeutic treatments for Fragile X Syndrome and Autism Spectrum Disorders. The company has […]

March 23, 2015 - 2 minutesmins - By Lourdes Riquelme

Knowledge hub

Categories

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Approaches

Therapeutic areas

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

R&D

BD

World biotech leaders

Connect with decision-makers and researchers worldwide for collaborative opportunities

Company

Join Us

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

#BioFigures: €406 Million Antibody-drug conjugate Deal struck by ImmunoGen andTakeda

Strategic Partnership Between Green Cross and Nanolek

OSE Pharma raised €21.1 Million

With €200 Million, Cellectis is on its way to make the Biggest French Biotech IPO ever

The Metamorphosis of Biopharmaceutical Innovation #BIO-Europe2015

Apceth Initiates Phase II for its pioneering Engineered Cell Therapy to treat Gastrointestinal Cancer

The Genomic Portrait of Iceland

Epigenomics’ proColon, the non-invasive blood-based test for colorectal cancer

The Institut Pasteur and IntegraGen, allies to Strengthen High-Throughput Sequencing in Microbiology

Rigontec and its revolutionary RNA-based immunotherapeutics raise €4.8 Million

Life Sciences have a new big player: Joint Polish Investment Fund Management

AOP Orphan and Confluence Pharmaceuticals, together for Fragile X Syndrome

Subscribe to our newsletter to get the latest biotech news!

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Catalonia: A biotech hub going from strength to strength, with Barcelona at its core

Top biotech deals of February 2025

Join the webinar: AI in antibody discovery - from in silico analysis to AI-enabled data management

These 7 biotechs are shaping the next generation of endometriosis care

Connect with decision-makers and researchers worldwide for collaborative opportunities

Subscribe to our newsletter

Advertise with us

Subscribe to our newsletter

Get the latest biotech news directly to your inbox!

Newsletter Signup - Footer

Subscribe to our newsletter to get the latest biotech news!